MedTrace Logo

Statin Use in Abdominal Aortic Aneurysm Repair

NCT01062802 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-02-25

No results posted yet for this study

Summary

Aneurysm formation is associated with a chronic inflammatory response, depletion of smooth muscle cell population and excessive matrix metalloproteinases (MMPs) production. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are lipid lowering agents with pleiotropic effects including anti-inflammatory activity. Elective open AAA repair patients will be randomised to receive either statin (Atorvastatin 80 mg) or placebo (dummy tablet) for 4 weeks pre-operatively. Tissue samples will be obtained from patient's aneurysm to assess MMP's and their inhibitors TIMP's. It is hypothesized that patients receiving statin will have reduced MMP's.

Conditions

  • Abdominal Aortic Aneurysm

Interventions

DRUG

Atorvastatin

Atorvastatin 80mg, once a day for four weeks.

OTHER

Placebo

Placebo given once daily for 4 weeks.

Sponsors & Collaborators

  • University of Hull

    lead OTHER

Principal Investigators

  • Ian C Chetter, MBChB, FRCS · Hull Royal Infirmary, Hull, United Kingdom.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2008-06-30
Completion
2008-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01062802 on ClinicalTrials.gov